U.S. markets closed
  • S&P Futures

    4,216.00
    +2.25 (+0.05%)
     
  • Dow Futures

    33,766.00
    +5.00 (+0.01%)
     
  • Nasdaq Futures

    14,136.00
    +6.00 (+0.04%)
     
  • Russell 2000 Futures

    2,279.30
    -1.60 (-0.07%)
     
  • Crude Oil

    73.63
    -0.03 (-0.04%)
     
  • Gold

    1,784.90
    +2.00 (+0.11%)
     
  • Silver

    25.94
    -0.08 (-0.33%)
     
  • EUR/USD

    1.1908
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    1.4840
    +0.0340 (+2.34%)
     
  • Vix

    17.89
    -2.81 (-13.57%)
     
  • GBP/USD

    1.3910
    -0.0023 (-0.16%)
     
  • USD/JPY

    110.3800
    +0.0820 (+0.07%)
     
  • BTC-USD

    32,583.91
    -2,761.10 (-7.81%)
     
  • CMC Crypto 200

    784.46
    -65.89 (-7.75%)
     
  • FTSE 100

    7,062.29
    +44.82 (+0.64%)
     
  • Nikkei 225

    28,724.21
    +713.28 (+2.55%)
     

Valneva Concludes Recruitment for COVID-19 Vaccine Candidate Trial

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Privately-held Valneva SE has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

  • VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, combined with two adjuvants, alum and Dynavax Technologies Corporation’s (NASDAQ: DVAX) CpG 1018.

  • Over 4,000 volunteers in the U.K. have been randomized in the Phase 3 trial “Cov-Compare,” which compares Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca Plc’s (NASDAQ: AZN) conditionally approved vaccine, Vaxzevria1.

  • Topline data are expected by September 2021, and submission to the U.K.’s Medicines and Healthcare products Regulatory Agency for regulatory approval will follow.

  • Price Action: DVAX shares are up 2.02% at $8.59 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.